Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Алгоритм ведения взрослых пациентов с инфекцией Helicobacter pylori
Алгоритм ведения взрослых пациентов с инфекцией Helicobacter pylori
Дехнич Н.Н., Хохлова Ю.А. Алгоритм ведения взрослых пациентов с инфекцией Helicobacter pylori. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019; 1: 22–28.
DOI: 10.26442/26583739.2019.1.190293
Consilium Medicum. 2019; 1: 22–28.
DOI: 10.26442/26583739.2019.1.190293
DOI: 10.26442/26583739.2019.1.190293
________________________________________________
Consilium Medicum. 2019; 1: 22–28.
DOI: 10.26442/26583739.2019.1.190293
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В настоящем обзоре представлен алгоритм ведения взрослых пациентов с инфекцией Helicobacter pylori. В помощь врачу описаны методы первичной диагностики возбудителя, схемы эмпирической антихеликобактерной терапии 1 и 2-й линии с учетом имеющихся данных чувствительности H. pylori к антимикробным препаратам в Российской Федерации, а также оптимальные методы контроля эффективности эрадикационной терапии. Продемонстрированы варианты эмпирической терапии 3-й линии при невозможности определения чувствительности H. pylori к антибиотикам.
Ключевые слова: Helicobacter pylori, гистологический метод, устойчивость к антимикробным препаратам, кларитромицин, метронидазол.
Key words: Helicobacter pylori, histological method, antimicrobial resistance, clarithromycin, metronidazole.
Ключевые слова: Helicobacter pylori, гистологический метод, устойчивость к антимикробным препаратам, кларитромицин, метронидазол.
________________________________________________
Key words: Helicobacter pylori, histological method, antimicrobial resistance, clarithromycin, metronidazole.
Полный текст
Список литературы
1. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: Perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014; 10: 628–38.
2. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Лечение инфекции Helicobacter pylori: Мейнстрим и новации. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (4): 4–21.
[Ivashkin V.T., Maev I.V., Lapina T.L. et al. Lechenie infektsii Helicobacter pylori: Meinstrim i novatsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 4–21 (in Russian).]
3. Didelot X, Nell S, Yang I et al. Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci U S A 2013; 110: 13880–5.
4. Urita Y, Watanabe T, Kawagoe N et al. Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town. J Paediatr Child Health 2013; 49: 394–8.
5. Capelle LG, de Vries AC, Looman CWN et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470–6.
6. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011; 29: 459–64.
7. Yuan W, Li Yumin, Yang Kehu et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
8. Sato R, Murakami K, Okimoto T et al. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol 2011; 46: 991–7.
9. Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013; 368: 2041–2.
10. Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United European Gastroenterol J 2015; 3: 429–31.
11. Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and noninvasive tests. Best Pract Res Clin Gastroenterol 2007; 21: 299–313.
12. Ferwana M, Abdulmajeed I, Alhajiahmed A et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol 2015; 21: 1305–14.
13. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921–30.
14. Moayyedi PM, Lacy BE, Andrews CN et al.: ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112 (7): 988–1013.
15. Smith S, Boyle B, Brennan D et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol 2017; 29 (5): 552–9.
16. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2018; 28 (1): 55–70.
[Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2018; 28 (1): 55–70 (in Russian).]
17. Gatta L, Vakil N, Ricci C et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823–9.
18. Malfertheiner P, Megraud F, O’Morain C et al. Management of Helicobacter pylori infection–Maastricht V/Florence consensus report. Gut 2017; 66 (1): 6–30.
19. Vaira D, Vakil N, Menegatti M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136: 280–7.
20. Chey WD, Metz DC, Shaw S et al. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 1171–4.
21. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1–15.
22. Симаненков В.И., Захарова Н.В., Жебрун А.Б. и др. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Лечащий врач. 2015; 4: 91–5.
[Simanenkov V.I., Zakharova N.V., Zhebrun A.B. et al. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezul'tatam bakteriologicheskogo testirovaniia. Lechashchii vrach. 2015; 4: 91–5 (in Russian).]
23. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
24. Chey WD, Leontiadis GI, Howden CW et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–38.
25. Luther J, Higgins PD, Schoenfeld PS et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65–73.
26. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23 (3): 830–93.
27. Shiota S, Reddy R, Alsarraj A et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13: 1616–24.
28. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147 (8): 553–62.
29. Yuan Y, Ford AC, Khan KJ et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868–77.
31. Choi HS, Park DIl, Hwang SJ et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007; 12: 638–42.
32. McNicholl AG, Linares PM, Nyssen OP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
33. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
34. Dore MP, Farina V, Cuccu M et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16: 295–300.
35. De Francesco V, Ierardi E, Hassan C et al. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012; 3 (4): 68–73.
36. Yanai A, Sakamoto K, Akanuma M et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3 (1): 1–6.
37. Дехнич Н.Н., Иванчик Н.В., Козлов Р.С. и др. Антибиотикорезистентность Helicobacter pylori в Смоленске. Клин. микробиология и антимикробная химиотерапия. 2018; 20 (1): 42–8.
[Dekhnich N.N., Ivanchik N.V., Kozlov R.S. et al. Antibiotikorezistentnost' Helicobacter pylori v Smolenske. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2018; 20 (1): 42–8 (in Russian).]
38. Саблин О.А., Михайлов Н.В., Юрин М.В. и др. Первичная резистентность Helicobacter pylori к антибиотикам в Санкт-Петербурге. Эксперимент. и клин. гастроэнтерология. 2012; 8: 18–23.
[Sablin O.A., Mikhailov N.V., Iurin M.V. et al. Pervichnaia rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterburge. Eksperiment. i klin. gastroenterologiia. 2012; 8: 18–23 (in Russian).]
39. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
40. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
2. Ivashkin V.T., Maev I.V., Lapina T.L. et al. Lechenie infektsii Helicobacter pylori: Meinstrim i novatsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 4–21 (in Russian).
3. Didelot X, Nell S, Yang I et al. Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci U S A 2013; 110: 13880–5.
4. Urita Y, Watanabe T, Kawagoe N et al. Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town. J Paediatr Child Health 2013; 49: 394–8.
5. Capelle LG, de Vries AC, Looman CWN et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470–6.
6. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011; 29: 459–64.
7. Yuan W, Li Yumin, Yang Kehu et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
8. Sato R, Murakami K, Okimoto T et al. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol 2011; 46: 991–7.
9. Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013; 368: 2041–2.
10. Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United European Gastroenterol J 2015; 3: 429–31.
11. Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and noninvasive tests. Best Pract Res Clin Gastroenterol 2007; 21: 299–313.
12. Ferwana M, Abdulmajeed I, Alhajiahmed A et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol 2015; 21: 1305–14.
13. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921–30.
14. Moayyedi PM, Lacy BE, Andrews CN et al.: ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112 (7): 988–1013.
15. Smith S, Boyle B, Brennan D et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol 2017; 29 (5): 552–9.
16. Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2018; 28 (1): 55–70 (in Russian).
17. Gatta L, Vakil N, Ricci C et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823–9.
18. Malfertheiner P, Megraud F, O’Morain C et al. Management of Helicobacter pylori infection–Maastricht V/Florence consensus report. Gut 2017; 66 (1): 6–30.
19. Vaira D, Vakil N, Menegatti M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136: 280–7.
20. Chey WD, Metz DC, Shaw S et al. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 1171–4.
21. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1–15.
22. Simanenkov V.I., Zakharova N.V., Zhebrun A.B. et al. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezul'tatam bakteriologicheskogo testirovaniia. Lechashchii vrach. 2015; 4: 91–5 (in Russian).
23. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
24. Chey WD, Leontiadis GI, Howden CW et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–38.
25. Luther J, Higgins PD, Schoenfeld PS et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65–73.
26. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23 (3): 830–93.
27. Shiota S, Reddy R, Alsarraj A et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13: 1616–24.
28. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147 (8): 553–62.
29. Yuan Y, Ford AC, Khan KJ et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868–77.
31. Choi HS, Park DIl, Hwang SJ et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007; 12: 638–42.
32. McNicholl AG, Linares PM, Nyssen OP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
33. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
34. Dore MP, Farina V, Cuccu M et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16: 295–300.
35. De Francesco V, Ierardi E, Hassan C et al. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012; 3 (4): 68–73.
36. Yanai A, Sakamoto K, Akanuma M et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3 (1): 1–6.
37. Dekhnich N.N., Ivanchik N.V., Kozlov R.S. et al. Antibiotikorezistentnost' Helicobacter pylori v Smolenske. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2018; 20 (1): 42–8 (in Russian).
38. Sablin O.A., Mikhailov N.V., Iurin M.V. et al. Pervichnaia rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterburge. Eksperiment. i klin. gastroenterologiia. 2012; 8: 18–23 (in Russian).
39. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
40. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
2. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Лечение инфекции Helicobacter pylori: Мейнстрим и новации. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (4): 4–21.
[Ivashkin V.T., Maev I.V., Lapina T.L. et al. Lechenie infektsii Helicobacter pylori: Meinstrim i novatsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 4–21 (in Russian).]
3. Didelot X, Nell S, Yang I et al. Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci U S A 2013; 110: 13880–5.
4. Urita Y, Watanabe T, Kawagoe N et al. Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town. J Paediatr Child Health 2013; 49: 394–8.
5. Capelle LG, de Vries AC, Looman CWN et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470–6.
6. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011; 29: 459–64.
7. Yuan W, Li Yumin, Yang Kehu et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
8. Sato R, Murakami K, Okimoto T et al. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol 2011; 46: 991–7.
9. Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013; 368: 2041–2.
10. Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United European Gastroenterol J 2015; 3: 429–31.
11. Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and noninvasive tests. Best Pract Res Clin Gastroenterol 2007; 21: 299–313.
12. Ferwana M, Abdulmajeed I, Alhajiahmed A et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol 2015; 21: 1305–14.
13. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921–30.
14. Moayyedi PM, Lacy BE, Andrews CN et al.: ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112 (7): 988–1013.
15. Smith S, Boyle B, Brennan D et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol 2017; 29 (5): 552–9.
16. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2018; 28 (1): 55–70.
[Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2018; 28 (1): 55–70 (in Russian).]
17. Gatta L, Vakil N, Ricci C et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823–9.
18. Malfertheiner P, Megraud F, O’Morain C et al. Management of Helicobacter pylori infection–Maastricht V/Florence consensus report. Gut 2017; 66 (1): 6–30.
19. Vaira D, Vakil N, Menegatti M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136: 280–7.
20. Chey WD, Metz DC, Shaw S et al. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 1171–4.
21. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1–15.
22. Симаненков В.И., Захарова Н.В., Жебрун А.Б. и др. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Лечащий врач. 2015; 4: 91–5.
[Simanenkov V.I., Zakharova N.V., Zhebrun A.B. et al. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezul'tatam bakteriologicheskogo testirovaniia. Lechashchii vrach. 2015; 4: 91–5 (in Russian).]
23. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
24. Chey WD, Leontiadis GI, Howden CW et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–38.
25. Luther J, Higgins PD, Schoenfeld PS et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65–73.
26. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23 (3): 830–93.
27. Shiota S, Reddy R, Alsarraj A et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13: 1616–24.
28. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147 (8): 553–62.
29. Yuan Y, Ford AC, Khan KJ et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868–77.
31. Choi HS, Park DIl, Hwang SJ et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007; 12: 638–42.
32. McNicholl AG, Linares PM, Nyssen OP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
33. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
34. Dore MP, Farina V, Cuccu M et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16: 295–300.
35. De Francesco V, Ierardi E, Hassan C et al. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012; 3 (4): 68–73.
36. Yanai A, Sakamoto K, Akanuma M et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3 (1): 1–6.
37. Дехнич Н.Н., Иванчик Н.В., Козлов Р.С. и др. Антибиотикорезистентность Helicobacter pylori в Смоленске. Клин. микробиология и антимикробная химиотерапия. 2018; 20 (1): 42–8.
[Dekhnich N.N., Ivanchik N.V., Kozlov R.S. et al. Antibiotikorezistentnost' Helicobacter pylori v Smolenske. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2018; 20 (1): 42–8 (in Russian).]
38. Саблин О.А., Михайлов Н.В., Юрин М.В. и др. Первичная резистентность Helicobacter pylori к антибиотикам в Санкт-Петербурге. Эксперимент. и клин. гастроэнтерология. 2012; 8: 18–23.
[Sablin O.A., Mikhailov N.V., Iurin M.V. et al. Pervichnaia rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterburge. Eksperiment. i klin. gastroenterologiia. 2012; 8: 18–23 (in Russian).]
39. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
40. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
________________________________________________
2. Ivashkin V.T., Maev I.V., Lapina T.L. et al. Lechenie infektsii Helicobacter pylori: Meinstrim i novatsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 4–21 (in Russian).
3. Didelot X, Nell S, Yang I et al. Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci U S A 2013; 110: 13880–5.
4. Urita Y, Watanabe T, Kawagoe N et al. Role of infected grandmothers in transmission of Helicobacter pylori to children in a Japanese rural town. J Paediatr Child Health 2013; 49: 394–8.
5. Capelle LG, de Vries AC, Looman CWN et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470–6.
6. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis 2011; 29: 459–64.
7. Yuan W, Li Yumin, Yang Kehu et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010; 45: 665–76.
8. Sato R, Murakami K, Okimoto T et al. Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura. J Gastroenterol 2011; 46: 991–7.
9. Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013; 368: 2041–2.
10. Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United European Gastroenterol J 2015; 3: 429–31.
11. Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and noninvasive tests. Best Pract Res Clin Gastroenterol 2007; 21: 299–313.
12. Ferwana M, Abdulmajeed I, Alhajiahmed A et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol 2015; 21: 1305–14.
13. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921–30.
14. Moayyedi PM, Lacy BE, Andrews CN et al.: ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112 (7): 988–1013.
15. Smith S, Boyle B, Brennan D et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol 2017; 29 (5): 552–9.
16. Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2018; 28 (1): 55–70 (in Russian).
17. Gatta L, Vakil N, Ricci C et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823–9.
18. Malfertheiner P, Megraud F, O’Morain C et al. Management of Helicobacter pylori infection–Maastricht V/Florence consensus report. Gut 2017; 66 (1): 6–30.
19. Vaira D, Vakil N, Menegatti M et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136: 280–7.
20. Chey WD, Metz DC, Shaw S et al. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 1171–4.
21. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1–15.
22. Simanenkov V.I., Zakharova N.V., Zhebrun A.B. et al. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezul'tatam bakteriologicheskogo testirovaniia. Lechashchii vrach. 2015; 4: 91–5 (in Russian).
23. Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646–64.
24. Chey WD, Leontiadis GI, Howden CW et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–38.
25. Luther J, Higgins PD, Schoenfeld PS et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65–73.
26. Feng L, Wen MY, Zhu YJ et al. Sequential therapy or standard triple therapy for Helicobacter pylori infection: an updated systematic review. Am J Ther 2016; 23 (3): 830–93.
27. Shiota S, Reddy R, Alsarraj A et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13: 1616–24.
28. Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147 (8): 553–62.
29. Yuan Y, Ford AC, Khan KJ et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12: CD008337.
30. Villoria A, Garcia P, Calvet X et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868–77.
31. Choi HS, Park DIl, Hwang SJ et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter 2007; 12: 638–42.
32. McNicholl AG, Linares PM, Nyssen OP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 (5): 414–25.
33. Ford AC, Malfertheiner P, Giguere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008; 14: 7361–70.
34. Dore MP, Farina V, Cuccu M et al. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011; 16: 295–300.
35. De Francesco V, Ierardi E, Hassan C et al. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012; 3 (4): 68–73.
36. Yanai A, Sakamoto K, Akanuma M et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3 (1): 1–6.
37. Dekhnich N.N., Ivanchik N.V., Kozlov R.S. et al. Antibiotikorezistentnost' Helicobacter pylori v Smolenske. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2018; 20 (1): 42–8 (in Russian).
38. Sablin O.A., Mikhailov N.V., Iurin M.V. et al. Pervichnaia rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterburge. Eksperiment. i klin. gastroenterologiia. 2012; 8: 18–23 (in Russian).
39. Liao J, Zheng Q, Liang X et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18: 373–7.
40. Chung JW, Lee JH, Jung HY et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011; 16: 289–94.
Авторы
Н.Н.Дехнич, Ю.А.Хохлова
ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России, Смоленск, Россия
Smolensk State Medical University, Smolensk, Russia
ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России, Смоленск, Россия
________________________________________________
Smolensk State Medical University, Smolensk, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.